Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 9,500 shares at $153.53 ($1.6M) on 2021-12-07, disclosed to the SEC on 2021-12-09.
Open-market sale of $1.6M NVAX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $150.30 | 200 | $30K | 1.9% |
| 2 | $151.85 | 100 | $15K | 0.9% |
| 3 | $153.53 | 397 | $61K | 3.8% |
| 4 | $153.53 | 397 | $61K | 3.8% |
| 5 | $154.38 | 100 | $15K | 1.0% |
| 6 | $156.24 | 300 |
| $47K |
| 2.9% |
| 7 | $157.02 | 200 | $31K | 1.9% |
| 8 | $158.42 | 300 | $48K | 2.9% |
| 9 | $160.52 | 300 | $48K | 3.0% |
| 10 | $161.63 | 300 | $48K | 3.0% |
| 11 | $162.83 | 200 | $33K | 2.0% |
| 12 | $164.77 | 300 | $49K | 3.1% |
| 13 | $165.80 | 300 | $50K | 3.1% |
| 14 | $167.06 | 300 | $50K | 3.1% |
| 15 | $168.77 | 400 | $68K | 4.2% |
| 16 | $171.30 | 200 | $34K | 2.1% |
| 17 | $173.14 | 200 | $35K | 2.1% |
| 18 | $175.13 | 900 | $158K | 9.7% |
| 19 | $176.20 | 800 | $141K | 8.7% |
| 20 | $178.21 | 500 | $89K | 5.5% |
| 21 | $179.36 | 500 | $90K | 5.5% |
| 22 | $180.29 | 500 | $90K | 5.6% |
| 23 | $182.30 | 853 | $156K | 9.6% |
| 24 | $182.30 | 853 | $156K | 9.6% |
| 25 | $182.96 | 100 | $18K | 1.1% |
| Total | $170.54 avg | 9,500 | $1.6M | 100% |
| Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |
| NVAX | SELL | 2021-11-24 | $2.5M | — | Filing → |